| Name | Title | Contact Details |
|---|
The Storch-Murphy Group is a Englewood, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Headquartered in Roxboro, N.C., Open Book Extracts is a cGMP-certified manufacturer of premium plant-based cannabinoid products, aiming to be the industry`s true north by delivering premium products, exceptional service, and industry-leading transparency. With control of the entire supply chain, a state-of-the-art extraction campus near North Carolina`s Research Triangle, proprietary refinement and conversion methods backed by a growing IP portfolio, and a team of PhD chemists and seasoned business leaders, OBX is the trusted partner for global brands seeking to enter the marketplace. OBX Asia, with its headquarters in Hong Kong, provides strategic guidance and on-the-ground support for our Asia customers. OBX`s cGMP-certified productions operations are led by a seasoned science team, including a PhD food scientist from Cornell, a PhD organic chemist from the University of Nevada, and two masters chemists with pharmaceutical backgrounds, including a quality control director who joined OBX after a 15-year career as an analytical chemist at GlaxoSmithKline. OBX offers one of the largest portfolios of cannabinoid isolates at 99%+ purity, including CBD, CBG, CBN, CBC, and THCV, as well as formulation services and turnkey finished good manufacturing including edibles, softgels, tablets, tinctures, pet products, and topical products.
Pure Power Athletics, Inc. d/b/a Makkar Athletics Group is a Oakville, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Rockwell Medical Supply is a Lomita, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.